Medicine Matters oncology

Resiquimod is a small organic molecule belonging to a class of imidazoquinolines, which has potent antiviral and anticancer activities. It is a stimulator of toll-like receptors 7/8 that are expressed by myeloid-derived dendritic cells. In a recent phase I trial, topical resiquimod gel was shown to be an effective therapy for early-stage CTCL, inducing regression of both treated and untreated lesions [5]. Current trials are exploring safety and efficacy of topical resiquimod gel 0.06% and 0.03% for patients with stage IA–IIA disease.